Evaluating the effectiveness of biological treatments in rheumatoid arthritis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with rheumatoid arthritis who are treated with targeted synthetic and biologic disease-modifying drugs. The study aims to assess the persistence and effectiveness of various medications, including JAK inhibitors and monoclonal antibodies, over a follow-up period of up to 84 months. Patients will be monitored through regular consultations to evaluate their health outcomes and treatment responses. The goal is to gather data on how these treatments impact the long-term health of patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥18 years.
* With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
* Who have received at least one of the doses of the study drugs.
* In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
* With at least two complete evaluations (baseline and final) of clinical variables.

Exclusion Criteria:

* Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
* Patients in whom more than 50% of the variables to be collected are missing in the data collection.

Where it's running

• Hospital Universitario Virgen macarena
  Seville, Spain Recruiting

Study contacts

• Principal investigator: Blanca Estela Hernández Cruz — Hospital Universitario Virgen Macarena
• Study coordinator: Blanca Estela Hernández Cruz
• Email: blancahcruz@gmail.com
• Phone: 955008000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collarless Actis hip stem for cementless hip replacement in Asian patients

  This study tests how well a collarless Actis hip stem works in adults undergoing primary hip replacement, focusing on outcomes over five years in an East Asian population.

  Recruiting Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07828080

• BMS-986528 in people with hard-to-treat rheumatoid arthritis

  This study tests BMS-986528 to see if it is safe and tolerable and to gather early data on how it behaves in the body and whether it might slow rheumatoid arthritis.

  Recruiting at 10 sites Phase 1/2 Bristol-Myers Squibb · La Jolla, California and 38 other locations · NCT07412704

• Fucoidan for active rheumatoid arthritis

  This trial will test whether fucoidan, a seaweed-derived SR-A inhibitor, can reduce disease activity in adults (18–65) with active rheumatoid arthritis who have moderate-to-high disease activity despite current treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07045896

• Abdominal vagus nerve stimulation for moderate to severe drug-refractory rheumatoid arthritis

  This trial will try a small implanted device that stimulates the abdominal vagus nerve to see if it is safe and possibly helpful for adults whose moderate to severe rheumatoid arthritis has not responded to medicines.

  Recruiting at 3 sites The Bionics Institute of Australia · Fitzroy, Victoria and 2 other locations · NCT07017686

• Effects of phytocannabinoids on immune response in chronic inflammatory diseases

  This study is testing whether phytocannabinoids like CBD and THC can help improve the immune response in people with chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

  Recruiting Centre Hospitalier Régional d'Orléans · Orléans · NCT06842316

• Individualized tapering strategy for rheumatoid arthritis treatment

  This study is testing a personalized plan for reducing medication in people with rheumatoid arthritis who are in remission to see if it helps prevent flare-ups.

  Recruiting at 6 sites Phase 4 Centre Hospitalier Universitaire de Saint Etienne · Caluire-et-Cuire and 7 other locations · NCT06528431

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.